Antimicrobial peptides (AMPs), which
can be modified to kill a
broad spectrum of microoganisms or a specific microorganism, are considered
as promising alternatives to combat the rapidly widespread, resistant
bacterial infections. However, there are still several obstacles to
overcome. These include toxicity, stability, and the ability to interfere
with the immune response and bacterial resistance. To overcome these
challenges, we herein replaced the regular peptide bonds with isopeptide
bonds to produce new AMPs based on the well-known synthetic peptides
Amp1L and MSI-78 (pexiganan). Two new peptides Amp1EP and MSIEP were
generated while retaining properties such as size, sequence, charge,
and molecular weight. These new peptides have reduced toxicity toward
murine macrophage (RAW 264.7) cells, human monocytic (THP-1) cells,
and human red blood cells (hRBCs) and enhanced the stability toward
proteolytic degradation. Importantly, the new peptides do not repress
the pro-inflammatory cytokine and hence should not modulate the immune
response. Structurally, the new peptides, Amp1EP and MSIEP, have a
structure of random coils in contrast to the helical structures of
the parental peptides as revealed by circular dichroism (CD) analysis.
Their mode of action, assessed by flow cytometry, includes permeabilization
of the bacterial membrane. Overall, we present here a new approach
to modulate AMPs to develop antimicrobial peptides for future therapeutic
purposes.